EGFR and non-small cell lung carcinoma: Several studies demonstrated the suitability of the assessment of molecular alterations by cfDNA analysis in patients with advanced NSCLC (aNSCLC), leading the European Medicine Agency to approve cfDNA testing for EGFR mutations analysis in case of tumor tissue unavailability [29].